INNOVATIVE GENE TARGETING - FROM ORGANELLE TRANSFER TO CRISPR/Cas
Room: JAN WILLEM SCHAAPFOYER
Time: Tuesday, 13:30 to 15:30
Chair(s): Amalia Dolga, Ingrid Dijkgraaf
Organizing FIGON partner(s): NVF, NVKFB
Current advances in life science have been supported by gene-editing and organelle transfer technologies. In particular, targeting modified genes or molecular pathways in human incurable diseases, have been recently received tremendous attention. Our session covers and addresses a broad range of research topics ranging from gene therapy, mitochondrial replacement therapy/mitochondrial donation, CRISPR/Cas9 and antibodies-based therapies. The clustered regularly interspaced short palindromic repeats (CRISPR)– associated protein 9 (CRISPR/ Cas9) system is a technology that provides the ability to add or remove DNA in the genome in a sequence-specific manner. In addition, adeno-associated virus (AAV) is one of the most actively investigated and used gene therapyvehicles for many diseases. As an alternative to recombinant protein administration, monoclonal antibody therapy has been considered as an attractive approach for the treatment of a variety of chronic diseases and migraine. These topics will be covered in presentations provided by researchers from academia and industry (SME).